Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights
09 nov. 2021 08h00 HE
|
Shattuck Labs, Inc.
– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials...
Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
04 nov. 2021 07h00 HE
|
Shattuck Labs, Inc.
– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET – AUSTIN, TX and DURHAM, NC, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage...
Shattuck Labs Announces Participation in Upcoming November Investor Conferences
03 nov. 2021 17h19 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Changes to its Board of Directors
28 oct. 2021 16h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
01 oct. 2021 09h56 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Participation in Upcoming September Conferences
01 sept. 2021 16h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252
11 août 2021 16h30 HE
|
Shattuck Labs, Inc.
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for...
Shattuck Labs Announces Participation in the BTIG Biotechnology Conference
06 août 2021 10h40 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021
04 août 2021 08h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer
01 juin 2021 10h44 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...